Literature DB >> 7850716

Angiotropic large cell lymphoma presenting as thrombotic microangiopathy (thrombotic thrombocytopenic purpura).

H Sill1, G Höfler, P Kaufmann, J Horina, E Spuller, R Kleinert, C Beham-Schmid.   

Abstract

BACKGROUND: Angiotropic large cell lymphoma is a rare lymphoproliferative disorder that affects vessels of almost all organs. Therefore, many different signs and symptoms can be observed and may delay a rapid diagnosis in these patients. However, no association between angiotropic large-cell lymphoma and thrombotic microangiopathy (TMA) has been reported so far.
METHODS: The case report describes a 69-year-old female Caucasian who presented with fever, neurologic symptoms, microangiopathic hemolytic anemia, thrombocytopenia, and hyaline thrombi within small vessels. TMA was diagnosed and intense treatment, including plasma exchange and corticosteroid therapy, was initiated. Nevertheless, the patient died 3 days after admission. A postmortem examination including immunohistochemistry and molecular studies was performed.
RESULTS: Autopsy revealed angiotropic large cell lymphoma with tumor cell aggregates in small vessels of the brain, myocardium, lungs, liver, small and large intestines, mesenterium, kidneys, and lymph nodes. Immunohistochemical analysis of the tumor cells showed positive reactions with B-cell markers, but negative T-cell and epithelial cell markers. Molecular studies using polymerase chain reaction with primers for the rearranged immunoglobulin heavy chain and the T-cell receptor beta chain gene confirmed the diagnosis of a monoclonal B-cell disorder.
CONCLUSION: TMA can occur in association with angiotropic large cell lymphoma and, furthermore, can be its sole clinical manifestation.

Entities:  

Mesh:

Year:  1995        PMID: 7850716     DOI: 10.1002/1097-0142(19950301)75:5<1167::aid-cncr2820750517>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab.

Authors:  Masatoshi Kanno; Shinobu Nakamura; Makoto Kawahara; Satoshi Ueno; Hirokazu Nakamine; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Int J Hematol       Date:  2008-08-19       Impact factor: 2.490

2.  Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.

Authors:  Rebecca L Ruebner; Lawrence Copelovitch; Nicholas F Evageliou; Michelle R Denburg; Jean B Belasco; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-12-07       Impact factor: 3.714

Review 3.  Disseminated carcinoma diagnosed by bone marrow biopsy in patients with microangiopathic hemolytic anemia and thrombocytopenia: a report of two cases with gastric cancer and a review of the literature.

Authors:  Orit Kaidar-Person; Haitam Nasrallah; Nissim Haim; Eldad J Dann; Gil Bar-Sela
Journal:  J Gastrointest Cancer       Date:  2011-09

Review 4.  Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Authors:  Han-Mou Tsai
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

5.  Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: a case report and review of the literature.

Authors:  Francisco Socola; Arturo Loaiza-Bonilla; Ernesto Bustinza-Linares; Ricardo Correa; Joseph D Rosenblatt
Journal:  Case Rep Oncol Med       Date:  2012-10-02

Review 6.  The thrombotic microangiopathies.

Authors:  Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2007-09-30       Impact factor: 3.714

Review 7.  How I treat microangiopathic hemolytic anemia in patients with cancer.

Authors:  M R Thomas; M Scully
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.